Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 154

1.

The anaesthetic xenon partially restores an amyloid beta-induced impairment in murine hippocampal synaptic plasticity.

Bürge M, Kratzer S, Mattusch C, Hofmann C, Kreuzer M, Parsons CG, Rammes G.

Neuropharmacology. 2019 Jun;151:21-32. doi: 10.1016/j.neuropharm.2019.03.031. Epub 2019 Mar 30.

PMID:
30940537
2.

CNS repurposing - Potential new uses for old drugs: Examples of screens for Alzheimer's disease, Parkinson's disease and spasticity.

Parsons CG.

Neuropharmacology. 2019 Mar 15;147:4-10. doi: 10.1016/j.neuropharm.2018.08.027. Epub 2018 Aug 27. Review.

PMID:
30165077
3.

The NMDA receptor antagonist Radiprodil reverses the synaptotoxic effects of different amyloid-beta (Aβ) species on long-term potentiation (LTP).

Rammes G, Seeser F, Mattusch K, Zhu K, Haas L, Kummer M, Heneka M, Herms J, Parsons CG.

Neuropharmacology. 2018 Sep 15;140:184-192. doi: 10.1016/j.neuropharm.2018.07.021. Epub 2018 Aug 11.

PMID:
30016667
4.

Preclinical to phase II amyloid beta (Aβ) peptide modulators under investigation for Alzheimer's disease.

Parsons CG, Rammes G.

Expert Opin Investig Drugs. 2017 May;26(5):579-592. doi: 10.1080/13543784.2017.1313832. Review.

PMID:
28362514
5.

Involvement of GluN2B subunit containing N-methyl-d-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta (Aβ) in murine models of Alzheimer's disease (AD).

Rammes G, Mattusch C, Wulff M, Seeser F, Kreuzer M, Zhu K, Deussing JM, Herms J, Parsons CG.

Neuropharmacology. 2017 Sep 1;123:100-115. doi: 10.1016/j.neuropharm.2017.02.003. Epub 2017 Feb 4.

PMID:
28174113
6.

Perspectives of Canadian fitness professionals on exercise and possible anorexia nervosa.

Wojtowicz AE, Alberga AS, Parsons CG, von Ranson KM.

J Eat Disord. 2015 Nov 17;3:40. doi: 10.1186/s40337-015-0074-y. eCollection 2015.

7.

Brain concentrations of mGluR5 negative allosteric modulator MTEP in relation to receptor occupancy--Comparison to MPEP.

Nagel J, Greco S, Parsons CG, Flik G, Tober C, Klein KU, Danysz W.

Pharmacol Rep. 2015 Jun;67(3):624-30. doi: 10.1016/j.pharep.2015.01.004. Epub 2015 Jan 22.

PMID:
25933979
8.

Effects of sarizotan in animal models of ADHD: challenging pharmacokinetic-pharmacodynamic relationships.

Danysz W, Flik G, McCreary A, Tober C, Dimpfel W, Bizot JC, Kostrzewa R, Brown RW, Jatzke CC, Greco S, Jenssen AK, Parsons CG.

J Neural Transm (Vienna). 2015 Sep;122(9):1221-38. doi: 10.1007/s00702-015-1392-6. Epub 2015 Mar 22.

PMID:
25796190
9.

MRZ-99030 - A novel modulator of Aβ aggregation: II - Reversal of Aβ oligomer-induced deficits in long-term potentiation (LTP) and cognitive performance in rats and mice.

Rammes G, Gravius A, Ruitenberg M, Wegener N, Chambon C, Sroka-Saidi K, Jeggo R, Staniaszek L, Spanswick D, O'Hare E, Palmer P, Kim EM, Bywalez W, Egger V, Parsons CG.

Neuropharmacology. 2015 May;92:170-82. doi: 10.1016/j.neuropharm.2014.12.037. Epub 2015 Jan 28.

PMID:
25637092
10.

MRZ-99030 - A novel modulator of Aβ aggregation: I - Mechanism of action (MoA) underlying the potential neuroprotective treatment of Alzheimer's disease, glaucoma and age-related macular degeneration (AMD).

Parsons CG, Ruitenberg M, Freitag CE, Sroka-Saidi K, Russ H, Rammes G.

Neuropharmacology. 2015 May;92:158-69. doi: 10.1016/j.neuropharm.2014.12.038. Epub 2015 Jan 26.

PMID:
25634238
11.
12.

Memantine and cholinesterase inhibitors: complementary mechanisms in the treatment of Alzheimer's disease.

Parsons CG, Danysz W, Dekundy A, Pulte I.

Neurotox Res. 2013 Oct;24(3):358-69. doi: 10.1007/s12640-013-9398-z. Epub 2013 May 9. Review.

13.

GluN2A and GluN2B NMDA receptor subunits differentially modulate striatal output pathways and contribute to levodopa-induced abnormal involuntary movements in dyskinetic rats.

Mabrouk OS, Mela F, Calcagno M, Budri M, Viaro R, Dekundy A, Parsons CG, Auberson YP, Morari M.

ACS Chem Neurosci. 2013 May 15;4(5):808-16. doi: 10.1021/cn400016d. Epub 2013 Apr 23.

14.

Rationale for combining glutamatergic and cholinergic approaches in the symptomatic treatment of Alzheimer's disease.

Francis PT, Parsons CG, Jones RW.

Expert Rev Neurother. 2012 Nov;12(11):1351-65. doi: 10.1586/ern.12.124. Review.

PMID:
23234396
15.

Lipid raft integrity affects GABAA receptor, but not NMDA receptor modulation by psychopharmacological compounds.

Nothdurfter C, Tanasic S, Di Benedetto B, Uhr M, Wagner EM, Gilling KE, Parsons CG, Rein T, Holsboer F, Rupprecht R, Rammes G.

Int J Neuropsychopharmacol. 2013 Jul;16(6):1361-71. doi: 10.1017/S146114571200140X. Epub 2012 Dec 10.

16.

Assessment of the effects of NS11394 and L-838417, α2/3 subunit-selective GABA(A) [corrected] receptor-positive allosteric modulators, in tests for pain, anxiety, memory and motor function.

Hofmann M, Kordás KS, Gravius A, Bölcskei K, Parsons CG, Dekundy A, Danysz W, Dézsi L, Wittko-Schneider IM, Sághy K, Gyertyán I, Horváth C.

Behav Pharmacol. 2012 Dec;23(8):790-801. doi: 10.1097/FBP.0b013e32835a7c7e. Erratum in: Behav Pharmacol. 2013 Apr;24(2):153.

PMID:
23075708
17.

Alzheimer's disease, β-amyloid, glutamate, NMDA receptors and memantine--searching for the connections.

Danysz W, Parsons CG.

Br J Pharmacol. 2012 Sep;167(2):324-52. doi: 10.1111/j.1476-5381.2012.02057.x. Review.

18.

Synthesis of a series of γ-amino alcohols comprising an N-methyl isoindoline moiety and their evaluation as NMDA receptor antagonists.

Müller A, Höfner G, Renukappa-Gutke T, Parsons CG, Wanner KT.

Bioorg Med Chem Lett. 2011 Oct 1;21(19):5795-9. doi: 10.1016/j.bmcl.2011.07.119. Epub 2011 Aug 6.

PMID:
21875803
19.

Therapeutic significance of NR2B-containing NMDA receptors and mGluR5 metabotropic glutamate receptors in mediating the synaptotoxic effects of β-amyloid oligomers on long-term potentiation (LTP) in murine hippocampal slices.

Rammes G, Hasenjäger A, Sroka-Saidi K, Deussing JM, Parsons CG.

Neuropharmacology. 2011 May;60(6):982-90. doi: 10.1016/j.neuropharm.2011.01.051. Epub 2011 Feb 12.

PMID:
21310164
20.

Pharmacological characterization of MRZ-8676, a novel negative allosteric modulator of subtype 5 metabotropic glutamate receptors (mGluR5): focus on L: -DOPA-induced dyskinesia.

Dekundy A, Gravius A, Hechenberger M, Pietraszek M, Nagel J, Tober C, van der Elst M, Mela F, Parsons CG, Danysz W.

J Neural Transm (Vienna). 2011 Dec;118(12):1703-16. doi: 10.1007/s00702-010-0526-0. Epub 2010 Dec 16.

PMID:
21161716
21.

In vivo evidence for functional NMDA receptor blockade by memantine in rat hippocampal neurons.

Szegedi V, Juhász G, Parsons CG, Budai D.

J Neural Transm (Vienna). 2010 Oct;117(10):1189-94. doi: 10.1007/s00702-010-0471-y. Epub 2010 Sep 7.

PMID:
20821339
22.

Memantine improves cognition and reduces Alzheimer's-like neuropathology in transgenic mice.

Martinez-Coria H, Green KN, Billings LM, Kitazawa M, Albrecht M, Rammes G, Parsons CG, Gupta S, Banerjee P, LaFerla FM.

Am J Pathol. 2010 Feb;176(2):870-80. doi: 10.2353/ajpath.2010.090452. Epub 2009 Dec 30.

23.

Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1.

Noeske T, Trifanova D, Kauss V, Renner S, Parsons CG, Schneider G, Weil T.

Bioorg Med Chem. 2009 Aug 1;17(15):5708-15. doi: 10.1016/j.bmc.2009.05.072. Epub 2009 Jun 23.

PMID:
19574055
24.

Potency, voltage-dependency, agonist concentration-dependency, blocking kinetics and partial untrapping of the uncompetitive N-methyl-D-aspartate (NMDA) channel blocker memantine at human NMDA (GluN1/GluN2A) receptors.

Gilling KE, Jatzke C, Hechenberger M, Parsons CG.

Neuropharmacology. 2009 Apr;56(5):866-75. doi: 10.1016/j.neuropharm.2009.01.012. Epub 2009 Jan 21.

PMID:
19371579
25.

Pharmacodynamics of memantine: an update.

Rammes G, Danysz W, Parsons CG.

Curr Neuropharmacol. 2008 Mar;6(1):55-78. doi: 10.2174/157015908783769671.

26.

Memantine as an example of a fast, voltage-dependent, open channel N-methyl-D-aspartate receptor blocker.

Parsons CG, Gilling K.

Methods Mol Biol. 2007;403:15-36. doi: 10.1007/978-1-59745-529-9_2.

PMID:
18827985
27.

Blocking kinetics of memantine on NR1a/2A receptors recorded in inside-out and outside-out patches from Xenopus oocytes.

Parsons CG, Gilling KE, Jatzke C.

J Neural Transm (Vienna). 2008 Oct;115(10):1367-73. doi: 10.1007/s00702-008-0087-7. Epub 2008 Jul 8.

PMID:
18607526
28.

The fraction of activated N-methyl-D-aspartate receptors during synaptic transmission remains constant in the presence of the glutamate release inhibitor riluzole.

Rammes G, Zieglgänsberger W, Parsons CG.

J Neural Transm (Vienna). 2008 Aug;115(8):1119-26. doi: 10.1007/s00702-008-0059-y. Epub 2008 May 21.

29.

Memantine does not show intracellular block of the NMDA receptor channel.

Parsons CG, Gilling KE, Jatzke C.

Eur J Pharmacol. 2008 Jun 10;587(1-3):99-103. doi: 10.1016/j.ejphar.2008.03.053. Epub 2008 Apr 4.

PMID:
18456253
30.

Positive and negative modulation of group I metabotropic glutamate receptors.

Vanejevs M, Jatzke C, Renner S, Müller S, Hechenberger M, Bauer T, Klochkova A, Pyatkin I, Kazyulkin D, Aksenova E, Shulepin S, Timonina O, Haasis A, Gutcaits A, Parsons CG, Kauss V, Weil T.

J Med Chem. 2008 Feb 14;51(3):634-47. doi: 10.1021/jm0611298. Epub 2008 Jan 4.

PMID:
18173231
31.
32.

Virtual screening for selective allosteric mGluR1 antagonists and structure-activity relationship investigations for coumarine derivatives.

Noeske T, Jirgensons A, Starchenkovs I, Renner S, Jaunzeme I, Trifanova D, Hechenberger M, Bauer T, Kauss V, Parsons CG, Schneider G, Weil T.

ChemMedChem. 2007 Dec;2(12):1763-73.

PMID:
17868161
33.

A novel class of amino-alkylcyclohexanes as uncompetitive, fast, voltage-dependent, N-methyl-D-aspartate (NMDA) receptor antagonists--in vitro characterization.

Gilling K, Jatzke C, Wollenburg C, Vanejevs M, Kauss V, Jirgensons A, Parsons CG.

J Neural Transm (Vienna). 2007;114(12):1529-37. Epub 2007 Aug 31.

PMID:
17728997
34.

Agonist concentration dependency of blocking kinetics but not equilibrium block of N-methyl-D-aspartate receptors by memantine.

Gilling KE, Jatzke C, Parsons CG.

Neuropharmacology. 2007 Sep;53(3):415-20. Epub 2007 Jun 7.

PMID:
17632186
35.

Searching for drug scaffolds with 3D pharmacophores and neural network ensembles.

Renner S, Hechenberger M, Noeske T, Böcker A, Jatzke C, Schmuker M, Parsons CG, Weil T, Schneider G.

Angew Chem Int Ed Engl. 2007;46(28):5336-9. No abstract available.

PMID:
17604383
36.

Inhibition of the alpha9alpha10 nicotinic cholinergic receptor by neramexane, an open channel blocker of N-methyl-D-aspartate receptors.

Plazas PV, Savino J, Kracun S, Gomez-Casati ME, Katz E, Parsons CG, Millar NS, Elgoyhen AB.

Eur J Pharmacol. 2007 Jul 2;566(1-3):11-9. Epub 2007 Mar 24.

PMID:
17466293
37.

Neuroprotective activity of selective mGlu1 and mGlu5 antagonists in vitro and in vivo.

Szydlowska K, Kaminska B, Baude A, Parsons CG, Danysz W.

Eur J Pharmacol. 2007 Jan 5;554(1):18-29. Epub 2006 Oct 10.

PMID:
17109843
38.

Predicting compound selectivity by self-organizing maps: cross-activities of metabotropic glutamate receptor antagonists.

Noeske T, Sasse BC, Stark H, Parsons CG, Weil T, Schneider G.

ChemMedChem. 2006 Oct;1(10):1066-8. No abstract available.

PMID:
16986201
39.
40.

3-Nitropropionic acid toxicity in hippocampus: protection through N-methyl-D-aspartate receptor antagonism.

Karanian DA, Baude AS, Brown QB, Parsons CG, Bahr BA.

Hippocampus. 2006;16(10):834-42.

PMID:
16897723
41.
42.

The antiallodynic effect of NMDA antagonists in neuropathic pain outlasts the duration of the in vivo NMDA antagonism.

Christoph T, Schiene K, Englberger W, Parsons CG, Chizh BA.

Neuropharmacology. 2006 Jul;51(1):12-7. Epub 2006 Apr 17.

PMID:
16616769
43.

Excitatory amino acid neurotransmission.

Parsons CG, Danysz W, Zieglgänsberger W.

Handb Exp Pharmacol. 2005;(169):249-303.

PMID:
16594262
44.

mGlu1 and mGlu5 receptor antagonists lack anticonvulsant efficacy in rodent models of difficult-to-treat partial epilepsy.

Löscher W, Dekundy A, Nagel J, Danysz W, Parsons CG, Potschka H.

Neuropharmacology. 2006 Jun;50(8):1006-15. Epub 2006 Mar 24.

PMID:
16563443
45.

N-methyl-D-aspartate receptors mediate endogenous opioid release in enteric neurons after abdominal surgery.

Patierno S, Zellalem W, Ho A, Parsons CG, Lloyd KC, Tonini M, Sternini C.

Gastroenterology. 2005 Jun;128(7):2009-19.

PMID:
15940633
46.

New allosteric modulators of metabotropic glutamate receptor 5 (mGluR5) found by ligand-based virtual screening.

Renner S, Noeske T, Parsons CG, Schneider P, Weil T, Schneider G.

Chembiochem. 2005 Apr;6(4):620-5. No abstract available.

PMID:
15744765
47.

Peripherally acting NMDA receptor/glycineB site receptor antagonists inhibit morphine tolerance.

Danysz W, Kozela E, Parsons CG, Sladek M, Bauer T, Popik P.

Neuropharmacology. 2005 Mar;48(3):360-71. Epub 2005 Jan 25.

PMID:
15721168
48.

Glutamate in CNS disorders as a target for drug development: an update.

Parsons CG, Danysz W, Quack G.

Drug News Perspect. 1998 Nov;11(9):523-69.

PMID:
15616669
49.

Effects of low-affinity NMDA receptor channel blockers in two rat models of chronic pain.

Medvedev IO, Malyshkin AA, Belozertseva IV, Sukhotina IA, Sevostianova NY, Aliev K, Zvartau EE, Parsons CG, Danysz W, Bespalov AY.

Neuropharmacology. 2004 Aug;47(2):175-83.

PMID:
15223296
50.

Supplemental Content

Loading ...
Support Center